Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 1/2015

Open Access 01-03-2015 | Pleural Diseases and Mesothelioma (G Lee, Section Editor)

Discovery of new biomarkers for malignant mesothelioma

Authors: Jenette Creaney, Ian M. Dick, Bruce W. S. Robinson

Published in: Current Pulmonology Reports | Issue 1/2015

Login to get access

Abstract

Malignant mesothelioma is an asbestos-induced, aggressive tumour with limited treatment options and very poor outcome. Currently, there are no tumour biomarkers in widespread clinical use for this disease. Soluble mesothelin is the most intensively investigated mesothelioma biomarker and has been approved by the US FDA primarily as a tool for monitoring patient response and progression. Mesothelin is elevated in the blood and effusions of patients with mesothelioma, and is rarely elevated in people with benign disease with normal renal function. However, the sensitivity of mesothelin limits its use as a stand-alone tool for the screening of the asymptomatic asbestos-exposed population—one of the primary aims of mesothelioma biomarker studies. Thus, there is an intense research effort focused on the identification of new and/or novel biomarkers for mesothelioma. Some of the challenges associated with biomarker discovery in mesothelioma are discussed.
Literature
1.
Pavlou MP, Diamandis EP. Validation of candidate protein biomarkers. In: Ginsburg GS, Willard HF, editors. Genomic and personalized medicine. 1. 2nd ed. London: Elsevier; 2013. p. 263–70.CrossRef
2.
3.
4.
Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38:1420–4.CrossRefPubMed
5.
Moyer VA, Force USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157:900–4.CrossRefPubMed
6.
Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74:2460–7.CrossRefPubMed
7.
Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63. discussion -5.CrossRefPubMed
8.
Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer. 1994;57:90–7.CrossRefPubMed
9.
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.CrossRefPubMed
10.
Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006;15:1014–20.CrossRefPubMed
11.
Ho M, Onda M, Wang QC, et al. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev. 2006;15:1751.CrossRefPubMed
12.••
Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541–9. Meta-analysis confirming the consitency of mesothelin as a mesothelioma biomarker.CrossRefPubMedCentralPubMed
13.
Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–61.CrossRefPubMed
14.
Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100:1432–8.CrossRefPubMedCentralPubMed
15.
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.CrossRefPubMed
16.
Simpson RJ, Bernhard OK, Greening DW, et al. Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol. 2008;12:72–7.
17.••
Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–94. A mathematical approach to determining the requirements for biomarker validation.
18.
Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004;96:353–6.CrossRefPubMed
19.
Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5:142–9.CrossRefPubMed
20.
Rodriguez H, Tezak Z, Mesri M, et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem. 2010;56:237–43.CrossRefPubMed
21.
Regnier FE, Skates SJ, Mesri M, et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem. 2010;56:165–71.CrossRefPubMed
22.
Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27:633–41.CrossRefPubMedCentralPubMed
23.
Creaney J, Sneddon S, Dick IM, et al. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers. 2013;35:119–27.CrossRefPubMedCentralPubMed
24.
Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3:851–7.CrossRefPubMed
25.
Yamaguchi N, Hattori K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805–8.PubMed
26.
Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984–90.CrossRefPubMed
27.••
Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med. 2010;181:620–5. Meta-analysis confirming the consitency of mesothelin as a mesothelioma biomarker.
28.
Ostroff RM, Mehan MR, Stewart A, et al. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 2012;7:e46091.CrossRefPubMedCentralPubMed
29.
30.
31.
Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004;10:849–59.CrossRefPubMed
32.
Greillier L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375–90.CrossRefPubMed
33.
Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129–35.CrossRefPubMed
34.
Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer. 2005;49 Suppl 1:S99–103.CrossRefPubMed
35.
Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564–73.CrossRefPubMed
36.
Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–35.CrossRefPubMed
37.
38.
Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166:1827–40.CrossRefPubMedCentralPubMed
39.
Zhang J, Qiu S, Zhang Y, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012;32:5151–8.PubMed
40.
Mundt F, Johansson HJ, Forshed J, et al. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mol Cell Proteomics. 2014;13:701–15.CrossRefPubMedCentralPubMed
41.•
Hogdall C, Fung ET, Christensen IJ, et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol. 2011;123:308–13. The only approved biomarker identified using a proteomics platform.CrossRefPubMed
Metadata
Title
Discovery of new biomarkers for malignant mesothelioma
Authors
Jenette Creaney
Ian M. Dick
Bruce W. S. Robinson
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 1/2015
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-015-0106-8

Other articles of this Issue 1/2015

Current Pulmonology Reports 1/2015 Go to the issue

Pleural Diseases and Mesothelioma (C Gary Lee, Section Editor)

Adjunct strategies to enhance the efficacy of indwelling pleural catheters

Interventional Pulmonology (S Maceiras-Luis, Section Editor)

Indwelling pleural catheters

Sleeping and Breathing (T Lee-Chiong, Section Editor)

Obesity hypoventilation syndrome

Sleeping and Breathing (T Lee-Chiong, Section Editor)

Sleep-disordered breathing as a modifiable risk factor for cardiovascular disease

Sleeping and Breathing (T Lee-Chiong, Section Editor)

Sleep disorders in COPD

Pleural Diseases and Mesothelioma (G Lee, Section Editor)

Chemical pleurodesis for first presentation of primary spontaneous pneumothorax

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits